← Back to Screener
PMV Pharmaceuticals, Inc (PMVP)
Price$1.43
Favorite Metrics
Price vs S&P 500 (26W)-6.52%
Price vs S&P 500 (4W)-15.62%
Market Capitalization$73.59M
All Metrics
Book Value / Share (Quarterly)$1.96
P/TBV (Annual)0.47x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.38
Price vs S&P 500 (YTD)6.26%
EPS (TTM)$-1.48
10-Day Avg Trading Volume0.54M
EPS Excl Extra (TTM)$-1.48
EPS (Annual)$-1.48
ROI (Annual)-74.24%
Cash / Share (Quarterly)$2.12
ROA (Last FY)-66.70%
EBITD / Share (TTM)$-1.64
ROE (5Y Avg)-37.34%
Cash Flow / Share (Annual)$-1.38
P/B Ratio0.70x
P/B Ratio (Quarterly)0.64x
Net Income / Employee (Annual)$-1
ROA (TTM)-54.19%
EPS Incl Extra (Annual)$-1.48
Current Ratio (Annual)10.09x
Quick Ratio (Quarterly)9.89x
3-Month Avg Trading Volume0.52M
52-Week Price Return38.00%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$4.64
52-Week High$1.88
EPS Excl Extra (Annual)$-1.48
CapEx CAGR (5Y)-28.01%
26-Week Price Return2.22%
Quick Ratio (Annual)9.89x
13-Week Price Return21.05%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)10.09x
Enterprise Value$35.612
Book Value / Share Growth (5Y)-24.52%
Revenue / Employee (Annual)$0
Cash / Share (Annual)$2.12
3-Month Return Std Dev89.70%
Net Income / Employee (TTM)$-1
ROE (Last FY)-74.24%
EPS Basic Excl Extra (Annual)$-1.48
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.48
ROI (TTM)-59.07%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$5.38
Price vs S&P 500 (52W)2.91%
Year-to-Date Return10.40%
5-Day Price Return2.22%
EPS Normalized (Annual)$-1.48
ROA (5Y Avg)-33.86%
Month-to-Date Return11.29%
Cash Flow / Share (TTM)$-1.54
EBITD / Share (Annual)$-1.64
ROI (5Y Avg)-37.34%
EPS Basic Excl Extra (TTM)$-1.48
P/TBV (Quarterly)0.48x
P/B Ratio (Annual)0.64x
Book Value / Share (Annual)$1.96
Price vs S&P 500 (13W)18.19%
Beta1.42x
Revenue / Share (TTM)$0.00
ROE (TTM)-59.07%
52-Week Low$0.81
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.25
4.25
4.25
4.25
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
PMVPPMV Pharmaceuticals, Inc | — | — | — | — | $1.43 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.71 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.93x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
PMV Pharmaceuticals is a precision oncology company developing small molecule therapies targeting p53 mutations to treat cancer across multiple tumor types. Its lead program, rezatapopt, is being evaluated in combination with azacitidine, with additional candidates including PC14586 and PMV-586-101 in its pipeline.